Kenvue (NYSE:KVUE) Given New $22.00 Price Target at Barclays

Kenvue (NYSE:KVUE) had its price target reduced by Barclays from $23.00 to $22.00 in a research report released on Tuesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Several other equities research analysts also recently issued reports on KVUE. Redburn Atlantic started coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price objective for the company. Citigroup reiterated a “neutral” rating on shares of Kenvue in a research report on Friday, June 13th. Bank of America reduced their price target on Kenvue from $27.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday. Evercore ISI began coverage on Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price on the stock. Finally, UBS Group boosted their price target on Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Friday, May 9th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $24.71.

Kenvue Stock Performance

NYSE:KVUE opened at $21.88 on Tuesday. The firm has a 50 day moving average of $22.24 and a 200-day moving average of $22.29. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. Kenvue has a 1 year low of $17.85 and a 1 year high of $25.17. The stock has a market capitalization of $41.97 billion, a P/E ratio of 39.77, a price-to-earnings-growth ratio of 3.40 and a beta of 0.83.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. Kenvue’s revenue was down 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.28 EPS. As a group, sell-side analysts anticipate that Kenvue will post 1.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KVUE. Pittenger & Anderson Inc. purchased a new stake in Kenvue in the first quarter valued at $30,000. TruNorth Capital Management LLC acquired a new stake in Kenvue during the 1st quarter worth approximately $36,000. Truvestments Capital LLC purchased a new position in shares of Kenvue during the 1st quarter worth approximately $37,000. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after buying an additional 1,287 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich raised its holdings in shares of Kenvue by 120.6% in the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock worth $41,000 after acquiring an additional 929 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.